Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications

Figure 3 Therapeutic interventions for metabolic-associated fatty liver disease based on microbiota. Intestinal-centered therapy including antibiotics, bacterial metabolites, probiotics, engineered bacteria, bacteriophages, and fecal microbial transplantation can specifically interfere with intestinal microflora to re-establish the interface between the liver and the microbiome. MAFLD: Metabolic-associated fatty liver disease.